Journal of Oncology Pharmacy Practice最新文献_第6页

ISOPP CAPhO Symposium 2025 Abstracts. ISOPP CAPhO研讨会2025摘要。

IF 1 4区医学

Journal of Oncology Pharmacy Practice Pub Date : 2025-04-01 Epub Date: 2025-04-03 DOI: 10.1177/10781552251320013

引用次数: 0

Innovation in hospital pharmacy: Modeling the installation of automated dispensing systems based on an oncology hospital experience transfer. 医院药房的创新：基于肿瘤医院经验转移的自动配药系统安装模型。

IF 1 4区医学

Journal of Oncology Pharmacy Practice Pub Date : 2025-04-01 Epub Date: 2024-03-21 DOI: 10.1177/10781552241239593

Soumaya El Baraka, Ali Cherif Chefchaouni, Aya Bourdaime, Oumaima Lahlou, Yassir El Alaoui, Younes Rahali

{"title":"Innovation in hospital pharmacy: Modeling the installation of automated dispensing systems based on an oncology hospital experience transfer.","authors":"Soumaya El Baraka, Ali Cherif Chefchaouni, Aya Bourdaime, Oumaima Lahlou, Yassir El Alaoui, Younes Rahali","doi":"10.1177/10781552241239593","DOIUrl":"10.1177/10781552241239593","url":null,"abstract":"ObjectiveThis study explores automated dispensing systems (ADS) implementation in hospitals, focusing on experience transfer between the National Institute of Oncology of Rabat (NIO) and the specialties hospital of Rabat (SHR) to develop a transferable ADS installation and management model.MethodA retrospective implementation and experience data analysis of 3 years ADS implementation at NIO and a prospective planification for SHR new implementation on 6 months were employed. Data collection included pharmacist team reports, personnel interviews, direct observations, and information system data exports. The study focused on identifying challenges a plan-do-check-act (PDCA) cycle.ResultsThe analysis revealed overestimation in ADS needs at NIO about 42%, leading to: Resource exhaustion; Challenges in timeline installation staff training and management, Disruptions in data integration and Incident Reports. These issues underscored the importance of a phased, well-planned implementation process.DiscussionThe study highlighted the crucial role of many comprehensive strategies. In accordance with the results of several studies, this work demonstrates the benefits of ADS in reducing medication errors and enhancing resource management, while also pointing out the necessity for accurate system sizing, effective integration with hospital information systems, and comprehensive staff training.ConclusionThe experience transfer between NIO and SHR provides a valuable model for ADS implementation in hospital pharmacies, proposing optimizations on: Implementation process; Timelines and mapping; Risk management and incident reports; Staff training, sensibilization and change control.","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"388-396"},"PeriodicalIF":1.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140175145","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Study to evaluate awareness about medication errors and impact of an educational intervention among healthcare personnel in a cancer hospital. 研究评估一家癌症医院医护人员对用药错误的认识以及教育干预措施的影响。

IF 1 4区医学

Journal of Oncology Pharmacy Practice Pub Date : 2025-04-01 Epub Date: 2024-02-25 DOI: 10.1177/10781552241235898

Puskar Kunwor, Bijaya Basyal, Nabin Pathak, Pankaj Vaidya, Sudip Shrestha

{"title":"Study to evaluate awareness about medication errors and impact of an educational intervention among healthcare personnel in a cancer hospital.","authors":"Puskar Kunwor, Bijaya Basyal, Nabin Pathak, Pankaj Vaidya, Sudip Shrestha","doi":"10.1177/10781552241235898","DOIUrl":"10.1177/10781552241235898","url":null,"abstract":"IntroductionMedication errors (MEs) are preventable incidents that can result in harm to patients. Therefore, it is essential for healthcare professionals (HCPs) to be well-informed about MEs. This study aims to assess the awareness levels of HCPs and the impact of educational intervention on their understanding of MEs.MethodsResponses to a 17-question structured, self-administered questionnaire assessing the awareness of HCPs regarding fundamental aspects of MEs, ME reporting systems, and their ability to make recommendations for improving the system for handling the MEs were collected both before and after two weeks of educational intervention administration.ResultsOf a total of 114 HCPs who initially participated in the study, six dropped following the intervention. The awareness regarding the Class A questionnaire was good in most physicians (60%), nurses (60%), and pharmacists (57%) before the intervention, which improved postintervention, with physicians (80%), nurses (32%), and pharmacists (78%) demonstrating excellent awareness. The awareness level in the Class B questionnaire was also improved to excellent in most physicians (70%), pharmacists (85%), and nurses (85%) following the intervention, while it was excellent only in 50%, 35%, and 1% of physicians, pharmacists, and nurses, respectively, preintervention. In the Class C questionnaire, most physicians (40%) and nurses (60%) had good awareness, while pharmacists (35%) demonstrated excellent awareness preintervention. Postintervention, most physicians (70%), nurses (77%), and pharmacists (64%) exhibited excellent awareness.ConclusionMost oncology practice HCPs demonstrate a good to average level of awareness regarding MEs. Clinical pharmacists' educational interventions can significantly enhance awareness among HCPs concerning MEs.","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"347-354"},"PeriodicalIF":1.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139972218","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Bilateral epithelial keratopathy and punctate keratitis due to ribociclib. 利波昔布导致双侧上皮性角膜炎和点状角膜炎。

IF 1 4区医学

Journal of Oncology Pharmacy Practice Pub Date : 2025-04-01 Epub Date: 2024-11-21 DOI: 10.1177/10781552241301406

Neslihan Bayraktar Bilen, Bilge Tarım, Mualla Hamurcu, Döndü Melek Ulusoy

{"title":"Bilateral epithelial keratopathy and punctate keratitis due to ribociclib.","authors":"Neslihan Bayraktar Bilen, Bilge Tarım, Mualla Hamurcu, Döndü Melek Ulusoy","doi":"10.1177/10781552241301406","DOIUrl":"10.1177/10781552241301406","url":null,"abstract":"IntroductionThis report describes a rare occurrence of corneal epithelial keratopathy associated with ribociclib, a cyclin-dependent kinase 4/6 (CDK4/6) inhibitor widely used in breast cancer treatment.Case reportAn 83-year-old female with a recent breast cancer diagnosis presented with blurred vision during the third cycle of ribociclib treatment. Ocular examination revealed corneal epitheliopathy and fluorescein staining findings. Detailed assessments and comparisons were made with existing literature, identifying a few reported cases of vortex keratopathy linked to ribociclib. To the best of our knowledge, this is the first reported case of epitheliopathy.Management and OutcomeSince it decreased visual acuity, ribociclib treatment was discontinued in consultation with oncology. There was no regression in epithelopathy findings and visual acuity did not improve during follow-up visits.DiscussionThis report underscores the uncommon association between ribociclib and corneal epithelial keratopathy, emphasizing the need for comprehensive monitoring and collaboration between oncologists and ophthalmologists.","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"511-514"},"PeriodicalIF":1.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142681108","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Real-world evaluation of therapeutic anticoagulation for cancer-associated thromboembolism: A retrospective analysis. 治疗抗凝治疗癌症相关血栓栓塞的真实世界评价：回顾性分析。

IF 1 4区医学

Journal of Oncology Pharmacy Practice Pub Date : 2025-04-01 DOI: 10.1177/10781552251331559

Juri Chung, Joshua Park, Jamie Chin-Hon, Meredith Akerman, Alexander Hindenburg

{"title":"Real-world evaluation of therapeutic anticoagulation for cancer-associated thromboembolism: A retrospective analysis.","authors":"Juri Chung, Joshua Park, Jamie Chin-Hon, Meredith Akerman, Alexander Hindenburg","doi":"10.1177/10781552251331559","DOIUrl":"https://doi.org/10.1177/10781552251331559","url":null,"abstract":"BackgroundThrombosis is the second leading cause of death in cancer patients and treatment for thrombosis and prevention for secondary prophylaxis is anticoagulation. Low-molecular-weight heparin (LMWH) is more effective than vitamin K antagonists for the treatment of cancer-associated thromboembolism (CAT). Direct oral anticoagulants (DOACs) are non-inferior to dalteparin in treating CAT with similar major bleeding risks. Major guidelines recommend DOACs for CAT; however, data comparing individual DOACs to enoxaparin is lacking. The purpose of this study is to evaluate the efficacy and safety of DOACs compared to LMWH for CAT.MethodsA multi-site retrospective review was conducted in adult cancer patients with a CAT history who received either a DOAC (apixaban or rivaroxaban) or LMWH (enoxaparin). Primary efficacy and safety endpoints were recurrent thromboembolism and major bleeding occurrences. Secondary endpoints included time to subsequent CAT occurrence, time to first bleed event post initial CAT, and incidence of clinically relevant non-major and minor bleeding.ResultsA total of 102 patients were included in the study. There was no significant difference among the groups with respect to time to subsequent CAT (p = 0.5625). However, patients who received apixaban and rivaroxaban had a 2.39 times and 3.26 times higher risk of subsequent CAT respectively compared to those who received enoxaparin. Major bleeding rates were also not statistically significant (p = 0.465), despite enoxaparin having the highest rate at 8.8% and no rivaroxaban patients experiencing major bleeding.ConclusionNo differences were observed between rivaroxaban, apixaban, and enoxaparin in rates of recurrent venous thromboembolism (VTE) and bleeding.","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"10781552251331559"},"PeriodicalIF":1.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143764213","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

British Oncology Pharmacy Association Delphi consensus guidelines: Co-infusion of trometamol-containing calcium folinate (Leucovorin) with systemic anti-cancer treatments. 英国肿瘤药学协会德尔菲共识指南：在全身性抗癌治疗中联合输注含托美他莫的亚叶酸钙（亮菌甲素）。

IF 1 4区医学

Journal of Oncology Pharmacy Practice Pub Date : 2025-04-01 Epub Date: 2024-04-05 DOI: 10.1177/10781552241243360

Calum Polwart, Tim Root, Songül Tezcan, Sharon Meehan, Bill Wetherill, Chloë Waterson, Bruce Burnett, Rena Chauhan, Ibrahim Al-Modaris

{"title":"British Oncology Pharmacy Association Delphi consensus guidelines: Co-infusion of trometamol-containing calcium folinate (Leucovorin) with systemic anti-cancer treatments.","authors":"Calum Polwart, Tim Root, Songül Tezcan, Sharon Meehan, Bill Wetherill, Chloë Waterson, Bruce Burnett, Rena Chauhan, Ibrahim Al-Modaris","doi":"10.1177/10781552241243360","DOIUrl":"10.1177/10781552241243360","url":null,"abstract":"Drug stability and compatibility are critical factors influencing the cost and logistics of treatment delivery, therapeutic effectiveness, and patient safety. This is particularly significant in the realm of cancer chemotherapeutics, where stability and compatibility studies play a vital role in ensuring rational and safe medicine administration. Oxaliplatin, fluorouracil, and irinotecan, commonly used in various combinations for gastrointestinal cancers, are complemented by co-administration of folinic acid in certain protocols. Notably, some folinic acid preparations include trometamol as an excipient, potentially impacting the stability of the chemotherapeutic agents if infused concomitantly. This study seeks to establish guidelines for oncology multidisciplinary teams, addressing potential risks associated with the combination of trometamol-containing folinic acid and chemotherapeutics. To achieve this, a quantitative questionnaire was distributed to members of the British Oncology Pharmacy Association (BOPA) and non-BOPA members through an online survey. Nineteen healthcare professionals with oncology experience, comprising 18 pharmacists and one nurse, completed the questionnaires. Each participant rated the validity and clarity of statements on a 5-point scale. The Delphi process concluded after the fourth round, consolidating the findings and recommendations from the multidisciplinary team. Twelve recommendations for safe practice have been made.","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"473-480"},"PeriodicalIF":1.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140857082","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A real-world multicentre evaluation of atezolizumab plus platinum-etoposide chemotherapy as first-line treatment in patients with extensive-stage small cell lung cancer in Italy. 在意大利对阿特珠单抗联合铂类-依托泊苷化疗作为广泛期小细胞肺癌患者一线治疗的真实多中心评估。

IF 1 4区医学

Journal of Oncology Pharmacy Practice Pub Date : 2025-04-01 Epub Date: 2024-03-27 DOI: 10.1177/10781552241242096

Felice Musicco, Chiara Fulgenzio, Antonia La Malfa, Nicoletta Jannitti, Antonietta Vitiello, Silvia Carpano, Francesca Fusco, Federico Cappuzzo, Irene Terrenato, Isabella Sperduti, Piera Polidori, Domenico Tarantino, Lidia Di Cerbo, Marcello Pani, Valentina Isgrò, Ruggero Lasala

{"title":"A real-world multicentre evaluation of atezolizumab plus platinum-etoposide chemotherapy as first-line treatment in patients with extensive-stage small cell lung cancer in Italy.","authors":"Felice Musicco, Chiara Fulgenzio, Antonia La Malfa, Nicoletta Jannitti, Antonietta Vitiello, Silvia Carpano, Francesca Fusco, Federico Cappuzzo, Irene Terrenato, Isabella Sperduti, Piera Polidori, Domenico Tarantino, Lidia Di Cerbo, Marcello Pani, Valentina Isgrò, Ruggero Lasala","doi":"10.1177/10781552241242096","DOIUrl":"10.1177/10781552241242096","url":null,"abstract":"IntroductionThe aim of this study was to analyze real-life data from a cohort of adult patients receiving atezolizumab in combination with carboplatin and etoposide for first-line treatment of ES-SCLC, in order to assess relative dose intensity (RDI), time-to-treatment discontinuation (TTD), time-to-treatment failure (TTF), progression-free survival (PFS), overall survival (OS) of treatments as well as the correlation between these outcomes.MethodsAn observational retrospective study was conducted. All patients treated with atezolizumab combined with carboplatin and etoposide for first-line treatment of ES-SCLC were included. Median TTD, TTF, PFS and OS were calculated in our cohort of patient by the Kaplan Meier method.ResultsThe curves obtained with the Kaplan Meier method of TTF and TTD are substantially similar, indicating a good concordance of the information extracted by the two different data sources. This tendency was confirmed also when the TTD versus PFS curves were compared. The median OS registered was 11.8 months. Patients with no liver metastases showed a longer median time of OS than patients with liver metastases. The mean value of RDI for the entire cohort was 87.4%.ConclusionsOur study showed that TTD, calculated from the administration data is a useful proxy of TTF as registered in the clinical chart. TTD is a real-world outcome that can be used to demonstrate the efficacy of drugs used for administered therapies. It can be used as an end point for RWE studies, where the evaluation is less structured and standardized.","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"430-437"},"PeriodicalIF":1.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11986083/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140293816","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Horse antithymocyte globulin test doses and infusion reactions in adults with aplastic anemia: A multicenter retrospective experience. 马抗胸腺细胞球蛋白试验剂量和输注反应在成人再生障碍性贫血：一个多中心回顾性经验。

IF 1 4区医学

Journal of Oncology Pharmacy Practice Pub Date : 2025-04-01 Epub Date: 2025-01-15 DOI: 10.1177/10781552241309894

Lauren T Shinn, Charlotte B Wagner, Ruchi Desai, Bernard L Marini

{"title":"Horse antithymocyte globulin test doses and infusion reactions in adults with aplastic anemia: A multicenter retrospective experience.","authors":"Lauren T Shinn, Charlotte B Wagner, Ruchi Desai, Bernard L Marini","doi":"10.1177/10781552241309894","DOIUrl":"10.1177/10781552241309894","url":null,"abstract":"IntroductionHorse antithymocyte globulin carries a black box warning for life-threatening anaphylactic reactions, and prescribing information recommends test doses to identify patients at highest risk of this adverse effect. The predictive value of such test doses is not well validated, and practicality of use is unclear.MethodsThis was a planned secondary analysis of a multicenter, retrospective cohort study in adults with severe aplastic anemia being managed with horse antithymocyte globulin as part of their treatment regimen. Qualitative and quantitative descriptions of test doses and infusion reactions are summarized, alongside key institutional administration practices.ResultsOf 49 patients who received intradermal test doses, two experienced positive reactions and went onto receive their full horse antithymocyte globulin course through prolonged infusion time or desensitization. Infusion reaction rate in patients with negative test doses was 61%, corresponding to a negative predictive value of 39%. Premedication, infusion time, and infusion reaction management were similar across institutions.ConclusionHorse antithymocyte globulin has a high risk of infusion reactions that must be monitored and managed closely. However, test doses do not consistently predict who will experience an infusion reaction, and their practicality may be limited with current administration practices.","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"495-498"},"PeriodicalIF":1.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143007061","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Using simulation to improve pharmacy operators' handling of cytotoxic spills. 利用模拟技术提高药房操作员处理细胞毒性溢漏的能力。

IF 1 4区医学

Journal of Oncology Pharmacy Practice Pub Date : 2025-04-01 Epub Date: 2024-03-05 DOI: 10.1177/10781552241237441

Alexandra Garnier, Pascal Bonnabry, Lucie Bouchoud

{"title":"Using simulation to improve pharmacy operators' handling of cytotoxic spills.","authors":"Alexandra Garnier, Pascal Bonnabry, Lucie Bouchoud","doi":"10.1177/10781552241237441","DOIUrl":"10.1177/10781552241237441","url":null,"abstract":"IntroductionInternational Society of Oncology Pharmacy Practitioners guidelines recommend having standard operating procedures (SOPs) and initial and yearly retraining programs on cytotoxic spill handling for pharmacy operators (POs). This study aimed to create a simulation-based training (SBT) program on this subject and evaluate its impact on POs' real-life performance.MethodsRandomly formed pairs of POs underwent a 2.5-hour training program, including two simulation exercises (a broken cytotoxic vial on the floor and a leaking cytotoxic bag) in a simulated pharmacy production unit. Each participant applied the cytotoxic spill handling SOPs. The PO and trainer-pharmacist did a debriefing after each exercise. Satisfaction was recorded on a 0-to-100% scale. A 20-item questionnaire assessed general knowledge about cytotoxic spill handling before and after the training. One month before and one month after the training, the POs underwent a real-life test when the trainer broke a fake cytotoxic vial in the cytotoxic storage area. Their performance in applying the SOPs was assessed on a 20-point checklist, and the time to handle the spill was recorded.ResultsTwelve POs participated. Mean satisfaction score was 98.9%. Mean knowledge score improved from 10.8/20 (SD = 2.0) before training to 14.5/20 (SD = 1.6) after training (p < 0.05). Mean real-life SOP performance improved from 78.6% (SD = 7.4%) to 97.1% (SD = 5.2%) (p < 0.05). Mean time to handle cytotoxic spills decreased from 17.3 minutes (SD = 3.6 minutes) to 11.9 minutes (SD = 1.5 minutes) (p < 0.05).ConclusionPOs improved their knowledge and real-life competencies for handling cytotoxic spills. This training will be included in POs' initial and continuing training programs.","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"355-363"},"PeriodicalIF":1.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11986078/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140039678","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Change in hair texture with the use of pomalidomide for multiple myeloma: From straight to curly phenotype. 使用泊马度胺治疗多发性骨髓瘤时头发质地的变化：从直发到卷发

IF 1 4区医学

Journal of Oncology Pharmacy Practice Pub Date : 2025-04-01 Epub Date: 2024-11-25 DOI: 10.1177/10781552241299698

Annam Zahid, Constantin A Dasanu

{"title":"Change in hair texture with the use of pomalidomide for multiple myeloma: From straight to curly phenotype.","authors":"Annam Zahid, Constantin A Dasanu","doi":"10.1177/10781552241299698","DOIUrl":"10.1177/10781552241299698","url":null,"abstract":"IntroductionPomalidomide is used for treating multiple myeloma in patients who have relapsed after prior treatment with lenalidomide and a proteasome inhibitor. Common side effects include mild cytopenias, and deep vein thrombosis. While papulo-erythematous rash has been described, hair effects are rare with this class of agents.Case ReportWe describe a 56-year-old man who was diagnosed with multiple myeloma type IgD lambda six years prior. He responded very well to initial treatment with bortezomib-lenalidomide-dexamethasone. After two years, he had a recurrence that was treated with daratumumab-pomalidomide-dexamethasone, and he entered a stringent complete response (CR) within six months. Daratumumab was discontinued after twelve months, and he subsequently remained on maintenance therapy with pomalidomide. Three months into the maintenance regimen, he noticed a change in hair texture to curly, which continued to progress. Causality assessment linked this change to pomalidomide use via the Naranjo nomogram questionnaire, by scoring 5.Management and OutcomePomalidomide maintenance therapy was continued without any dose alterations given the excellent clinical outcome. A year later, multiple myeloma remains in stringent complete response. The patient remains with a curly hair phenotype, having fully embraced his new physical appearance.Discussion/ConclusionWe report herein a unique hair texture alteration linked with pomalidomide use, not previously documented in literature. The observed hair texture change, from straight to curly, requires further investigation. Future studies may offer more insights into the mechanisms underlying this rare, yet intriguing side effect.","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"507-510"},"PeriodicalIF":1.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142710481","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0